Avian metapneumovirus isolates and immunogenic compositions therefrom
AssigneeIowa State University Research Foundation, Inc.
InventorsJianqiang Zhang, Liying Tian, Phillip Gauger, Mohamed El-Gazzar, Yuko Sato
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to novel avian metapneumovirus (aMPV) isolates, including aMPV serially propagated in cell culture, all of which are useful in the preparation of immunogenic compositions and vaccines for treating and preventing disease in birds.
Claims26
An immunogenic composition comprising an inactivated or live attenuated avian metapneumovirus (aMPV), wherein the aMPV comprises a polynucleotide having at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% sequence identity to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16;
- and
- a pharmaceutically acceptable carrier.
A method for inducing an immune response against avian metapneumovirus (aMPV) in an avian subject comprising:
- administering to the avian subject an immunogenic composition comprising an inactivated or live attenuated aMPV, wherein the aMPV comprises a polynucleotide having at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% sequence identity to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16.
A DNA polynucleotide encoding an avian metapneumovirus (aMPV), or an immunogenic fragment thereof, wherein the aMPV comprises a polynucleotide having at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% sequence identity to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16.
A culture of cells comprising an avian metapneumovirus (aMPV), wherein the aMPV comprises a polynucleotide having at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% sequence identity to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16.
A method of preparing a live attenuated avian metapneumovirus (aMPV) comprising:
- passaging an aMPV in cell culture, wherein the aMPV comprises a polynucleotide having at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% sequence identity to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16.
A vaccine composition comprising an inactivated or live attenuated avian metapneumovirus (aMPV), wherein the aMPV comprises a polynucleotide having at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% sequence identity to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16;
- an adjuvant;
- and
- a pharmaceutically acceptable carrier.
A method for determining if an avian population is in need of vaccination against avian metapneumovirus (aMPV) infection:
- collecting a biological sample from one or more subjects of the avian population;
- and
- detecting the presence of the aMPV in the biological sample, wherein the aMPV comprises a polynucleotide having at least 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% sequence identity to SEQ ID NO:
- 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16.
Dependencies are inferred from the claim text.